Your central resource for federal health-plan updates, reimbursement policy changes, prior authorization trends, and access-related guidance affecting pharmaceutical reimbursement professionals.
Federal Watch helps professionals monitor policy areas that can affect access, coverage pathways, prior authorization, benefit design, specialty pharmacy, site of care, and affordability conversations.
It does not replace official payer policy, plan documents, legal or billing guidance, or medical decision-making.
FEATURED FEDERAL UPDATES
Latest Federal Watch Updates
Dated source statements preserved for local review. Currency and qualified subject-matter review remain pending.
CMS
CMS Issues Draft Guidance on Manufacturer Effectuation of the Maximum Fair Price in 2028
CMS issued draft guidance describing manufacturer access to Medicare-negotiated maximum fair prices for selected Part B and Part D drugs beginning in 2028, including operational detail involving the Medicare Transaction Facilitator, providers, dispensing entities, claim-level exchange, and refund workflows.
Access teams should monitor potential effects on provider-administered products, dispensing workflows, acquisition cost, Medicare Advantage data, and operational readiness.
CMS Launches Medicare GLP-1 Bridge, Expanding Access to GLP-1 Medications
This source-page headline is preserved as a dated draft record. Exact program detail and the controlling CMS destination require qualified review before publication or retrieval.
FEDERAL WATCH TOPIC
Electronic Prior Authorization: What Reimbursement Teams Should Watch in 2026–2027
Always verify final policy details directly with CMS before applying guidance to a reimbursement, access, coverage, or operational scenario.
LATEST FEDERAL WATCH UPDATES
Source-based operational awareness
CMS / PRIOR AUTHORIZATION
Electronic Prior Authorization: What Reimbursement Teams Should Watch in 2026–2027
CMS prior authorization and interoperability requirements are shifting the access-workflow conversation. These are operational questions ARMs and reimbursement leaders should monitor.
Medicare Prescription Payment Plan: Why It Matters for Part D Access Conversations
The Medicare Prescription Payment Plan allows Part D enrollees to spread out-of-pocket prescription-drug costs through monthly payments. Teams should understand where it fits, and where it does not.
Follow the program area, then verify the controlling source.
FED
TRICARE, FEHB & Other Federal Plans
Follow federal-plan resources that may affect pharmacy rules, prior authorization, plan comparisons, prescription coverage, and employee or retiree benefit considerations.
Monitor Medicaid pharmacy policy, the Medicaid Drug Rebate Program, state prescription-drug coverage, drug utilization review, preferred-drug lists, and prior authorization.
Track CMS guidance, Medicare Learning Network resources, Medicare Advantage, Part D, coverage processes, billing and compliance education, and related federal developments.
Compliance reminder: Requirements can change and vary by program, plan, geography, benefit channel, site of care, payer policy, and circumstance. Verify with official sources, plan documents, and organizational standards.
QUICK LINKS TO OFFICIAL RESOURCES
Start with the responsible publisher.
CMS / MEDICARE
Medicare Learning Network®
Official CMS education, training, publications, MLN Matters® articles, compliance resources, and Medicare Fee-for-Service updates.
Dated update summaries and program statements are governed drafts pending source-currency and qualified review. Official destinations may be used for navigation; the summaries are not approved for ARIA retrieval or consequential guidance.
